Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
AMLX Stock Chart & Stats
$14.98
-$0.14(-3.78%)
At close: 4:00 PM EST
$14.98
-$0.14(-3.78%)
Day’s Range― - ―
52-Week Range$2.60 - $16.96
Previous CloseN/A
Volume98.90K
Average Volume (3M)1.56M
Market Cap
$1.65B
Enterprise Value$930.34M
Total Cash (Recent Filing)$343.99M
Total Debt (Recent Filing)$5.93M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Apr 01, 2026EPS Estimate
-0.35Last Dividend Ex-Date
Mar 28, 2018Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding109,819,570
10 Day Avg. Volume1,493,358
30 Day Avg. Volume1,564,888
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.56
Price to Sales (P/S)2.95
P/FCF Ratio-1.53
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue-1.40K
Enterprise Value/Gross Profit-45.03
Enterprise Value/Ebitda-6.05
Forecast
1Y Price Target
$20.22Price Target Upside34.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline DiversificationAMX0114 represents a novel antisense approach in ALS, with early safety data expected to validate its mechanism and diversify Amylyx's pipeline.
Potential Market OpportunityEven with conservative patient estimates, the total market opportunity for a new therapy for PBH could easily exceed several billion dollars.
Regulatory DesignationsWith Breakthrough Therapy and Orphan designations, avexitide is positioned for premium pricing and rapid uptake if approved.
Bears Say
Enrollment DelayAmylyx now expects to complete enrollment of the Phase III LUCIDITY trial in Q1 2026, which is later than the previous guidance of the end of 2025.
Amylyx Pharmaceuticals Inc News
AMLX FAQ
What was Amylyx Pharmaceuticals Inc’s price range in the past 12 months?
Amylyx Pharmaceuticals Inc lowest stock price was $2.60 and its highest was $16.96 in the past 12 months.
What is Amylyx Pharmaceuticals Inc’s market cap?
Amylyx Pharmaceuticals Inc’s market cap is $1.65B.
When is Amylyx Pharmaceuticals Inc’s upcoming earnings report date?
Amylyx Pharmaceuticals Inc’s upcoming earnings report date is Apr 01, 2026 which is in 121 days.
How were Amylyx Pharmaceuticals Inc’s earnings last quarter?
Amylyx Pharmaceuticals Inc released its earnings results on Nov 06, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.436 by $0.066.
Is Amylyx Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amylyx Pharmaceuticals Inc’s price is currently Undervalued.
Does Amylyx Pharmaceuticals Inc pay dividends?
Amylyx Pharmaceuticals Inc pays a Quarterly dividend of $0.42 which represents an annual dividend yield of N/A. See more information on Amylyx Pharmaceuticals Inc dividends here
What is Amylyx Pharmaceuticals Inc’s EPS estimate?
Amylyx Pharmaceuticals Inc’s EPS estimate is -0.35.
How many shares outstanding does Amylyx Pharmaceuticals Inc have?
Amylyx Pharmaceuticals Inc has 109,819,570 shares outstanding.
What happened to Amylyx Pharmaceuticals Inc’s price movement after its last earnings report?
Amylyx Pharmaceuticals Inc reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.436. Following the earnings report the stock price went down -5.891%.
Which hedge fund is a major shareholder of Amylyx Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in AMLX
Amylyx Pharmaceuticals Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.22 (34.98% Upside)
$20.22 (34.98% Upside)
Blogger Sentiment
Bullish
AMLX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 10.2%
Last 30 Days ▼ 10.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
160.97%
12-Months-Change
Fundamentals
Return on Equity
-56.52%
Trailing 12-Months
Asset Growth
44.68%
Trailing 12-Months
Company Description
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
AMLX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment with strong financial performance and progress across multiple programs. However, there is a noted delay in the LUCIDITY trial enrollment, indicating some operational challenges. The urgency and unmet need in the PBH market further underscore the importance of avexitide's development.View all AMLX earnings summariesAMLX Stock 12 Month Forecast
Average Price Target
$20.22
▲(34.98% Upside)
Technical Analysis
BioCryst
―
Dianthus Therapeutics
―
Harmony Biosciences Holdings
―
Pharvaris
―
Biohaven Ltd.
―
Ownership Overview
7.46% Insiders
9.46% Mutual Funds
49.79% Other Institutional Investors
19.51% Public Companies and
Individual Investors